ClinicalTrials.gg
RecruitingNCT07550517Updated Sep 22, 2026

PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT

A Phase 2 interventional study of EBRT + 6 mo ADT + 177Lu-PSMA-617 and EBRT + 24 mo ADT in High-Risk Localized Prostate Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 78 studies in Prostatic Neoplasms by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — 12 open to participants now, 18 under way, none of them phase 3. Prostatic Neoplasms · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Planned enrollment
16th of 72
60 · median 25
Started
2026
with 3 others
Phase 2
31 of 78
6 open now
Primary completion
2032-08
later than 17 of 17 live
Registered
78th of 78
by date

Among the 78 studies in Prostatic Neoplasms by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, this one is the 16th largest by planned enrollment of the 72 interventional ones that give a count, is one of 4 that started in 2026, is one of 31 in phase 2, reaches primary completion later than 17 of the 17 other live ones, and was the 78th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

12 of the 78 studies in Prostatic Neoplasms by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Prostatic Neoplasms by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, or all of them as a file.
02

Study summary

This research is being done to find out if the study drug, 177Lu-PSMA-617, given before and during standard of care External Beam Radiation Therapy (EBRT) treatment, with a shorter course of Androgen Deprivation Therapy (ADT) (6 months) is (1) safe and effective compared to standard of care alone, and (2) can reduce the side effects caused by long-term (24 months) ADT in men with high risk localized prostate cancer.

Read the detailed description

Men with high-risk localized prostate cancer include those with stage cT3a or Grade Group 4/5 or Prostate Specific Antigen (PSA) >20 ng/mL, and the proportional rate of high-risk disease has increased to 20% of newly diagnosed patients in the US. These patients are currently recommended treatment with a combination of definitive radiotherapy and long-term androgen deprivation therapy (NCCN category 1) or radical prostatectomy with pelvic lymph node dissection. Radiotherapy most often consists of external-beam radiotherapy (EBRT) in 28 to 45 daily fractions with 1.5 to 3 years of ADT. Multiple phase III studies have shown a benefit in survival with long-term ADT. However, given the toxicities of long-term ADT, including fatigue, mood changes, sexual dysfunction, osteopenia, weight gain, diabetes and cardiovascular disease, many patients are reluctant to complete long-term ADT. This leads to significant demand for investigation of lower-toxicity alternatives to long-term ADT for patients with high-risk localized prostate cancer.

The combination of 177Lu-PSMA-617 with definitive EBRT and 6 months ADT for high-risk prostate cancer has the potential to increase the cumulative absorbed dose to the prostate, involved nodes, and micrometastatic disease, as well as decrease toxicity and improve QoL compared with EBRT and long-term ADT. ADT has been shown to increase radiosensitivity and PSMA expression of prostate cancer; therefore 6 months of ADT was selected to optimize the combination therapy while avoiding toxicities associated with long-term ADT. There are significant unknowns with respect to absorbed dose and toxicities of this potential combination of 177Lu-PSMA-617 and EBRT. In addition, the relative efficacy compared to EBRT plus long-term ADT is unknown. The investigators therefore propose a phase II randomized study of dosimetry, safety, and efficacy of Lu-177-PSMA-617, EBRT, and short-term ADT (6 months) in comparison with EBRT and long-term ADT (24 months).

03

Conditions studied

  • High-Risk Localized Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient must have high-risk prostate cancer (HRPC) defined by presence of exactly one high-risk feature: cT3a OR Grade Group 4 or 5 OR PSA > 20 ng/mL.
  • Histologic confirmation of adenocarcinoma of the prostate.
  • Patient must have localized HRPC defined by conventional imaging (no N1 disease by CT or MRI). Patients with or without intra-pelvic nodal by PSMA-PET may be included as long as not enlarged >10mm short axis by conventional CT size criteria.
  • Patients must have PSMA-PET (68Ga-PSMA-11 or 18F-DCFPyL) with prostate tumor SUVmax > 10.
  • Patient must qualify for definitive treatment of prostate cancer including EBRT as well as ADT (up to 45 days of prior ADT is allotted).
  • Patient must be ≥ 18 years of age.
  • Patient must have a ≥ 24 months.
  • Patient must have an (ECOG) performance status ≤ 2.
  • Adequate bone marrow reserve and organ function as demonstrated by complete blood count and chemistry panel completed within the prior 6 weeks demonstrating:

    1. count of >100 x109/L
    2. White blood cell (WBC) count > 3,000/mL
    3. of > 1,500/mL
    4. ≥ 10 g/dL
    5. Estimated (eGFR) > 50 mL/min based upon Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation. Due to safety concerns relating to renal clearance and toxicity of 177Lu-PSMA-617, patients with estimated GFR between 50 - 60 mL/min will require a 99mTc-TPA GFR test and only patients with non-obstructive pathology will be included in the study.
    6. Total \< 3 x (except if confirmed history of Gilbert's disease)
    7. Serum albumin > 30 g/L
    8. (AST) \< 3 times the ULN
  • For male patients with partners of , agreement to use barrier method (condom) and to continue its use for 6 months from receiving the last dose of 177Lu-PSMA-617.
  • Patient must have the ability to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  • Presence of a very high-risk feature: cT3b to T4 OR primary pattern 5 OR 2 to 3 high-risk features OR >4 cores with Grade Group 4 or 5.
  • Any prior pharmacotherapy (with the exception of up to 45 days of ADT prior to randomization), radiation therapy, or surgery as treatment for prostate cancer. Any prior radiopharmaceutical therapy.
  • Any prior radiation to the pelvis.
  • Presence of N1 or M1 disease by conventional imaging (CT, MRI, and/or bone scan) or M1 disease by PSMA-PET (68Ga-PSMA-11 or 18F-DCFPyL). Lymph nodes with short axis > 8 mm by CT will be considered N1 by conventional imaging.
  • Castration-resistant prostate cancer (CRPC).
  • Patient receiving any other agents.
  • Patient is participating in a concurrent treatment protocol involving radiotherapy, surgery, or systemic anti-cancer agents.
  • Inadequate bone marrow reserve and organ function as detailed in 5.1.10.
  • Unable to lie flat during or tolerate PET/MRI, PET/CT or EBRT.
  • Concurrent serious medical condition that, in the opinion of the Investigator, would impair study participation.
  • to receiving pelvic radiation, including history of or active inflammatory bowel disorders.
  • Refusal to sign .
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Arm A (EBRT + 6 mo ADT + 177Lu-PSMA-617)

    Participants will receive EBRT + 6 mo ADT + 177Lu-PSMA-617

    Drug: EBRT + 6 mo ADT + 177Lu-PSMA-617

  • Active comparator
    Arm B (EBRT + 24 mo ADT)

    Participants will receive EBRT + 24 mo ADT

    Radiation: EBRT + 24 mo ADT

Interventions

  • DrugEBRT + 6 mo ADT + 177Lu-PSMA-617

    In Arm A, 177Lu-PSMA-617 will be given as intravenous infusion every 6 weeks, up to 4 cycles. Cycle 1 Day 1 (C1D1) of 177Lu-PSMA-617 will start at least 2 weeks after ADT, and EBRT will start at least 2 weeks after C1D1.

  • RadiationEBRT + 24 mo ADT

    In Arm B, EBRT will start 3-7 weeks after Day 1 of ADT.

06

What researchers measure

Primary outcomes

  1. Rate of testosterone recovery (TR)

    The rate of testosterone recovery (TR) will be determined by the percentage of patients who recover normal T levels within 3 years after randomization.

    Time frame: Post randomization up to 3 years.

Secondary outcomes

  1. Biochemical disease-free survival (BC-DFS)

    Measured from randomization to the time of a measured PSA value at least 2 ng/mL above nadir, and at least 25% above nadir, or death, whichever occurs first.

    Time frame: From randomization up to 3 years.

  2. Time-to-Next-Intervention (TTNI)

    TTNI is defined as the period of time from randomization to the initiation of any additional cancer-directed therapy. In the absence of a defining event, TTNI will be censored at the date of last visit documenting absence of interventions.

    Time frame: From randomization up to 3 years.

  3. ADT-free survival (ADT-FS)

    ADT-free survival defined as the time from randomization to the time of initiation of palliative ADT or death, whichever occurs first.

    Time frame: From randomization up to 3 years.

  4. Metastasis-free survival (MFS)

    MFS is defined as the time from randomization to the time of detection of at least one new metastatic lesions on conventional imaging. Patients who do not develop at least one new metastasis will be censored at the time of the last disease assessment.

    Time frame: From randomization up to 3 years.

  5. Overall Survival (OS)

    For subjects who do not die, time to death will be censored at the time of last contact.

    Time frame: From randomization to the date of death, up to 3 years.

  6. Toxicity as assessed by adverse events

    Toxicity of combination therapy with EBRT + 6 mo ADT + 177Lu-PSMA-617 by collecting CTCAE v5.0 adverse events.

    Time frame: In Arm A, AEs assessed 7-10 days prior to every cycle of 177Lu-PSMA-617. In Arm B, AEs assessed at baseline, Day 1, EOT, and after the completion of EBRT. For both arms, starting at 6 months, AEs assessed every 6 months up to 5 years (no Month 54 f/u).

  7. Quality of Life as assessed by Expanded Prostate Index Composite (EPIC)

    Score range, 0-100. Higher score better quality of life.

    Time frame: Pre-treatment, end of RT, 6 months, and every 6 months thereafter up to 5 years (no Month 54 f/u).

  8. Quality of Life as assessed by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core 30

    Score range from 0 to 100. A higher score indicates better quality of life.

    Time frame: Pre-treatment, end of RT, 6 months, and every 6 months thereafter up to 5 years (no Month 54 f/u).

  9. Quality of Life as assessed by Xerostomia Quality of Life Scale (XeQoLS)

    Score range 0 to 60, with higher scores indicating worse quality of life.

    Time frame: Pre-treatment, end of RT, 6 months, and every 6 months thereafter up to 5 years (no Month 54 f/u).

  10. Correlation of Toxicities and Absorbed Dose

    To correlate rate of CTCAE v5.0 grade 3 toxicities with mean absorbed dose to normal organs at risk. Specifically, pelvic organ toxicities will be correlated with mean EBRT dose, mean Lu-PSMA absorbed dose and mean cumulative absorbed dose for the bladder, rectum, and bowel.

    Time frame: In Arm A, AEs assessed 7-10 days prior to every cycle of 177Lu-PSMA-617. In Arm B, AEs assessed at baseline, Day 1, EOT, and after the completion of EBRT. For both arms, starting at 6 months, AEs assessed every 6 months up to 5 years (no Month 54 f/u).

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Aug 2032, 72 months after the start.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 72 months is above that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2026
First posted
Apr 24, 2026
StartActual
Aug 17, 2026
Primary completionEst.
Aug 2032
CompletionEst.
Aug 2033
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07550517
Responsible party
Sponsor
First posted
Apr 24, 2026
Start date
Aug 17, 2026
Primary completion
Aug 2032 (estimated)
Completion
Aug 2033 (estimated)
Last update
Sep 22, 2026

Study contacts

Ana Kiess
Contact
akiess1@jhmi.edu
443-287-7528
Ryan Manuel
Contact
rmanuel5@jhmi.edu
410-955-4261
Ana Kiess
principal investigator · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion